Dr. Madhav Dhodapkar on IMiD-based Combinations in Multiple Myeloma

Madhav Dhodapkar, MBBS
Published: Thursday, Jun 02, 2016



Madhav Dhodapkar, MBBS, clinical research program leader in the Hematology Program at Yale Cancer Center, discusses the changing role of immunomodulatory drugs (IMiDs) in multiple myeloma.

IMiDs have clear immunologic effects, says Dhodapka. IMiD-based combinations offer a lot of potential. There is emerging data on combination checkpoint inhibitors with IMiDs which looks very promising. There is already data showing efficacy between IMiDs and monocolonal antibodies, another immune-targeting agent, says Dhodapka.

The ideal combinations may dependent on the individual patient, as each patient has a unique immune microenvironment. Immune-based combinations may need to be personalized based on molecular profiling, says Dhodapka.
 


Madhav Dhodapkar, MBBS, clinical research program leader in the Hematology Program at Yale Cancer Center, discusses the changing role of immunomodulatory drugs (IMiDs) in multiple myeloma.

IMiDs have clear immunologic effects, says Dhodapka. IMiD-based combinations offer a lot of potential. There is emerging data on combination checkpoint inhibitors with IMiDs which looks very promising. There is already data showing efficacy between IMiDs and monocolonal antibodies, another immune-targeting agent, says Dhodapka.

The ideal combinations may dependent on the individual patient, as each patient has a unique immune microenvironment. Immune-based combinations may need to be personalized based on molecular profiling, says Dhodapka.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x